Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 2/2013

01.02.2013 | Inflammatory Bowel Disease (SB Hanauer, Section Editor)

Clinical Outcomes and Management of Inflammatory Bowel Disease in the Older Patient

verfasst von: Christina Y. Ha, Seymour Katz

Erschienen in: Current Gastroenterology Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The management of inflammatory bowel disease in the older patient extends beyond the gastrointestinal tract. Pre-existing comorbidities, polypharmacy, functional status and physical reserve can impact disease course, response to therapy and quality of life. Current therapeutic endpoints may not be as immediately applicable to the older IBD patient at higher risk for adverse outcomes. This review focuses on the latest studies addressing the natural history, clinical course and therapeutic outcomes among the older IBD cohort.
Literatur
1.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef
2.
3.
Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.PubMedCrossRef
4.
Cacciapaglia F, Navarini L, Menna P, et al. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev. 2011;10:631–5.PubMedCrossRef
5.
Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug M`etabol Rev. 2009;41:67–76.CrossRef
6.
Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging. 2009;26:715–37.PubMedCrossRef
7.
Zarowitz BJ. Pharmacologic consideration of commonly used gastrointestinal drugs in the elderly. Gastroenterol Clin N Am. 2009;38:547–62.CrossRef
8.
Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.PubMedCrossRef
9.
al Mahdy H, Seymour DG. How much can elderly patients tell us about their medications? Postgrad Med J. 1990;66:116–21.PubMedCrossRef
10.
Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–61.PubMedCrossRef
11.
Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–43.PubMedCrossRef
12.
Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–8.PubMedCrossRef
13.
Charpentier C, Salleron J, Savoye G, et al. Natural history of Crohn's disease in the elderly: a population-based study. Gastroenterology. 2012;142(5):S26.
14.
Charpentier C, Salleron J, Savoye G, et al. Clinical and phenotypic characteristics of ulcerative colitis according to age: a population-based study. Gastroenterology. 2012;142:S24–5.
15.
Ha CY, Newberry RD, Stone CD, et al. Patients With Late-Adult-Onset Ulcerative Colitis Have Better Outcomes Than Those With Early Onset Disease. Clin Gastroenterol Hepatol 2010.
16.
Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn's disease phenotype. Age and ageing 2012.
17.
18.
Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133–9.PubMedCrossRef
19.
Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4586–91.PubMedCrossRef
20.
del Val JH. Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol: WJG. 2011;17:2734–9.PubMed
21.
Ha C, Bayless T, Bitton A, et al. Late adult-onset inflammatory bowel disease patients require surgery earlier during their disease course compared to early adult-onset patients. Gastroenterology. 2012;142(5):S253–4.
22.
Anathakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.CrossRef
23.
Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–80.PubMedCrossRef
24.
Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.PubMedCrossRef
25.
Tourner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.CrossRef
26.
Ananthakrishnan AN, McGinley EL, Binion DG, et al. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:176–82.PubMedCrossRef
27.
Navaneethan U, Parasa S, Venkatesh PG, et al. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. J Crohn's Colitis. 2011;5:189–95.CrossRef
28.
Ha C, Bayless T, Wick E. Increased incidence of post-operative complications in older inflammatory bowel disease patients having intestinal surgery. Gastroenterology. 2012;142(5):S25.
29.
Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959–64.PubMedCrossRef
30.
Bautista M, Otterson M, Zadvornova Y, et al. Surgical outcomes in the elderly with inflammatory bowel disease. Gastroenterology. 2012;142(5):S665–6.
31.
Feagins LA, Spechler SJ. Biologic agent use varies inversely with age at diagnosis in Crohn's disease. Dig Dis Sci. 2010;55:3164–70.PubMedCrossRef
32.
Cottone M, Kohn A, Daperno M, et al. Age is a Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2010.
33.
Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflammatory bowel diseases 2012.
34.
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.PubMedCrossRef
35.
Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohn's Colitis 2012.
36.
•• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT Registry. The American journal of gastroenterology 2012. This follow-up study to the original TREAT registry data underscores the importance of steroid-sparing agents for the older patient as both age and steroid use were associated with increased mortality. Infliximab and steroid use were associated with increased risk of severe infections which is also of concern for the older IBD patient.
37.
Bhushan A, Pardi D, Loftus E, et al. Association of age with adverse events from biologic therapy in patients with inflammatory bowel disease. Gastroenterology. 2010;138:A413.CrossRef
38.
Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis. 2011;17:1664–9.PubMedCrossRef
39.
Vargas SL, Pizarro P, Lopez-Vieyra M, et al. Pneumocystis colonization in older adults and diagnostic yield of single versus paired noninvasive respiratory sampling. Clin Infect Dis Offic Publ Infect Dis Soc America. 2010;50:e19–21.CrossRef
40.
Long MD, Farraye FA, Okafor P, et al. Risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Gastroenterology. 2012;142(5):S662.
41.
42.
Widdifield J, Bernatsky S, Michael Paterson J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis care & research 2012.
43.
Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.PubMedCrossRef
44.
Tseng HF, Smith N, Marcy SM, et al. Risk factors of herpes zoster among children immunized with varicella vaccine: results from a nested case–control study. Pediatr Infect Dis J. 2010;29:205–8.PubMedCrossRef
45.
• Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–9. This large retrospective cohort study investigated the safety and efficacy of the zoster vaccine, traditionally thought to be contraindicated in the setting of immunsuppression, among older patients—the highest risk group for disseminated disease and shingles.PubMedCrossRef
46.
Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483–90.PubMedCrossRef
47.
Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations Rep Centers Dis Contr. 2008;57:1–30. quiz CE2-4.
48.
Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74. 774 e1-4; quiz e12-3.PubMedCrossRef
49.
Baars JE, Kuipers EJ, van Haastert M, et al. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. Journal of gastroenterology 2012.
50.
Karvellas CJ, Fedorak RN, Hanson J, et al. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol. 2007;21:443–6.PubMed
51.
Shaukat A, Virnig DJ, Salfiti NI, et al. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case–control study. Dig Dis Sci. 2011;56:2378–83.PubMedCrossRef
52.
Gearhart SL, Nathan H, Pawlik TM, et al. Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a Surveillance Epidemiology and End Results Medicare study. Dis Colon Rectum. 2012;55:270–7.PubMedCrossRef
53.
Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.PubMedCrossRef
54.
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–28 e1-5. This cohort study identified the impact of thiopurines on skin cancer risk, which is especially important in the older patient who is at greater risk for skin cancers at baseline.PubMedCrossRef
55.
Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399 e1.PubMedCrossRef
56.
•• Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889–97. This article provides a comprehensive summary of the management of the older IBD patient in today's clinical practice with an emphasis on the fit versus frail model to consider in the elderly.PubMedCrossRef
57.
Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207–19.PubMed
58.
Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399–409.PubMedCrossRef
59.
60.
Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.PubMedCrossRef
61.
62.
Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–45.PubMedCrossRef
Metadaten
Titel
Clinical Outcomes and Management of Inflammatory Bowel Disease in the Older Patient
verfasst von
Christina Y. Ha
Seymour Katz
Publikationsdatum
01.02.2013
Verlag
Current Science Inc.
Erschienen in
Current Gastroenterology Reports / Ausgabe 2/2013
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-012-0310-4

Weitere Artikel der Ausgabe 2/2013

Current Gastroenterology Reports 2/2013 Zur Ausgabe

Liver (B Bacon, Section Editor)

Treatment of Hepatitis C: How Will We Use Viral Kinetics, Response-Guided Therapy?

Liver (B Bacon, Section Editor)

Natural History of Cirrhosis

Liver (B Bacon, Section Editor)

Role of Liver Biopsy in the Era of Direct-Acting Antivirals

Liver (B Bacon, Section Editor)

Portal Vein Thrombosis: Should Anticoagulation Be Used?

Liver (B Bacon, Section Editor)

An Update on the Hepatitis E Virus

Inflammatory Bowel Disease (SB Hanauer, Section Editor)

Novel Targets for Inflammatory Bowel Disease Therapeutics

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise